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*Mortality and incidence rate in laryngeal cancer.
*Treatment options for laryngeal cancers include surgery, radiotherapy, and
chemotherapy.
* In chemotherapy, DTX acts by stabilizing the microtubule apparatus,
thereby inhibiting cell division.
* Poor solubility and wide systemic side effects ,and multidrug resistance
(MDR) are a barrier of chemotherapeutic agents that reduces therapeutic
efficacy.
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*ABCG2 gene
*The therapeutic strategy was used here was a combination treatment.
*Liposome as carrier
* EGFR and overexpression in laryngeal cancer
*A novel peptide, GE11 (YHWYGYTPQNVI) was specificity against
EGFR proteins.
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*In this paper, DTX loaded within the hydrophobic lipid bilayer.
*ABCG2–siRNA polynucleotides were loaded on liposomal surfaces using
electrostatic interactions.
*Liposomal surfaces were also conjugated with GE11.
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Methods
1. Preparation of drug-loaded liposomes and peptide conjugations.
2. Particle size analyses.
3. Morphology analyses.
4. In vitro drug release assays.
5. In vitro cell viability assays of Hep-2 cells.
6. Apoptosis assays
7. Hoechst 33382 staining assays
8. In vivo anti-tumor efficacy studies
9. Statistical analyses
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1. Physicochemical analyses of GE11 peptide-conjugated DTX/ABCG2–
siRNA-loaded liposomes.
Results and discussion
 The mean diameters of DTX/liposomes were ~110 nm
 Conjugations of GE11 peptides increased NP sizes to approximately 150 nm
 Final DTX/ABCG2–siRNA-loaded NPs were of mean size ~180 nm.
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Results and discussion
GE11-conjugated DTX/ABCG2–siRNA loaded liposomes were slightly 
larger than DTX/liposomes and maintained spherical morphologies, 
indicating that surface modifications did not alter the shapes of the 
NPs.
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Results and discussion
2- Drug-release studies
 the in vitro drug release assays were determined by dialysis methods 
in PBS (pH 7.4) at 37°C 12
Results and discussion
3- Cellular uptake analyses
 Rhodamine-B fluorescence intensities were observed in cytoplasmic 
regions, suggesting that NPs were internalized via endocytosis-
mediated mechanisms. 13
Results and discussion
4- In vitro cytotoxic effects of GE11-targeted DTX/ABCG2-liposomal NPs
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5- Apoptosis assays 
Results and discussion
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6- Quantifications of nuclear apoptosis
 Nuclear apoptotic reactions of Hep-2 cancer cells were identified
 using Hoechst 33382 staining techniques. 
 The control cell nuclei remained the same size and shape while 
nuclei treated with the NP formulations became irregular and 
distorted in shape.
Results and discussion
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7- In vivo anti-tumor efficacy assays
Results and discussion
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1. The data presented here describe dual therapeutic-loaded GE11 peptide-
conjugated liposomes that enhanced the combined therapeutic efficacies of 
DTX and ABCG2– siRNA in laryngeal cancers.
2. GE11 surface peptides enhanced cellular uptake of the constructs in Hep-2 
laryngeal cancer cells.
3. Treatment of Hep-2 xenograft-implanted nude mice with the GDSL NP 
formulation led to smaller tumors than those observed in animals receiving 
non-targeted NP constructs.  
Conclusion
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